AXGN

Axogen is a genuinely good business priced for its quality. Revenue has compounded cleanly for four years ($127M→$139M→$159M→$187M→$225M), growing 20.2% in FY2025, and the gross margin is a biologic-grade 74.3%, so the unit economics are real. The pivotal development is structural, not financial: on December 3, 2025 the FDA approved the BLA for Avance, the product that drives ~60% of revenue. That converts the company's core franchise from a tissue allograft into an FDA-licensed biologic — a regulatory moat synthetic-conduit and unapproved-allograft competitors cannot easily match. The MD&A stacks two more forward tailwinds on top: a new CMS Level 3 Nerve Procedure Code effective Jan 1, 2026 lifting Avance facility reimbursement ~40% YoY, and commercial payer coverage now above 65% (≈19.8M new covered lives in 2025). The balance sheet also just got materially stronger — the January 2026 upsized offering brought in $133.3M net, $69.7M of which fully repaid and terminated the term loan.

The problem is the price and the absence of profit. At $44.72 the market cap is $2.32B, or 10.3x FY revenue, for a company that still loses money: net loss widened to -$15.7M (from -$10.0M), operating income swung to -$7.85M (down 138.8%), net margin is -7.0% and ROE is -12.2%. Some of that is one-time — ~$1.9M of BLA-approval costs (67% non-cash stock comp) compressed gross margin — but the core remains an unprofitable P&L with operating cash flow that collapsed 82% to a razor-thin $812K. Equity is supported by a $307M accumulated deficit, and shareholders keep getting diluted: shares outstanding rose 17% in FY2025, and the January raise adds 4.6M more.